Sponsors

Lead Sponsor

Istituto Oncologico Veneto IRCCS

FLOWER is a real-world, prospective, observational study enrolling patients with histological and/or cytological diagnosis of EGFR-mutant aNSCLC, receiving first-line treatment with the third-generation EGFR-TKI, osimertinib. All the patients received osimertinib at the recommended dose of 80 mg, orally, once a day. Dosing interruptions or reductions required, based on individual tolerability, were managed according to clinical practice in compliance with label indications. The FLOWER study aims at evaluating effectiveness, safety, progression pattern and clinical management of untreated EGFR-mutant aNSCLC patients in the real-world.

Related studies

RECRUITINGPhase 1/2

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

NCT06109558 · Non Small Cell Lung Cancer, RET Gene Mutation, and more

RECRUITINGNA

A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

NCT05033691 · NSCLC, EGFR Gene Mutation, and more

Active Not RecruitingPhase 1/2

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

NCT05256290 · Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, and more

Active Not RecruitingPhase 2

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

NCT04504071 · Non-small Cell Lung Cancer Metastatic, EGF-R Positive Non-Small Cell Lung Cancer

Not Yet RecruitingNA

The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC

NCT06287593 · EGF-R Positive Non-Small Cell Lung Cancer

View all related studies →

First Line Osimertinib in the Real World: an Inter-regional Prospective Study

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC

Trial snapshot

Condition

Locations shown

For caregivers